393 Results
Sort By:
Published on February 12, 2018
DiaCarta said today it has completed a $45 million Series B financing, with the proceeds to be used toward an expansion of its molecular diagnostic test offerings and NGS services. DiaCarta Founder and CEO Aiguo (Adam) Zhang, Ph.D., said in a statement that the company will use the capital it…
Published on February 12, 2018
Huntington's disease (HD) patients are an anomaly with respect to contracting cancer, with 80% fewer cases than found in the general population. Now, a team of investigators at Northwestern University Feinberg School of Medicine has discovered why HD is so toxic to cancer cells and are harnessing it as a…
Published on February 7, 2018
When cells go astray and stagger toward malignant fates, they leave behind the molecular equivalent of footprints. Some of the most telling footprints may be found along transcriptional pathways, but if the missteps are to be identified, they need to be distinguished from all the other molecular traces criss-crossing the…
Published on February 5, 2018
The Personal Genome Project Canada has released first results that suggest whole genome sequencing can benefit the country's quality of healthcare, based on the results of sequencing the entire personal genomes of 56 healthy participants. Those results, released Saturday, showed that one-quarter (14) of the 56 adult participants who had…
Published on January 9, 2018
Research from an international team of investigators has found that independent of the identical genes shared by monozygotic (MZ) twins, they also share epigenetic similarity that influences their characteristics. The study, “Epigenetic Supersimilarity of Monozygotic Twin Pairs”, published in Genome Biology—proposes a mechanism to explain the extra level of similarity…
Published on November 28, 2017
Biocept said today it will partner with University of California San Diego (UCSD) Medical Center on a clinical validation study of the company’s PD-L1 assay for patients diagnosed with non-small cell lung cancer (NSCLC). Under the collaboration, whose value was not disclosed, Sandip Patel, M.D., an assistant professor of UCSD…
Published on November 27, 2017
Royal Philips has announced a pair of technologies aimed at helping fight cancer—including the launch of the latest edition of its IntelliSpace Portal advanced visualization and quantification platform, and the development of a combined liquid biopsy/imaging approach for which a consortium led by the company has won a €6.3 million…
Published on November 6, 2017
Researchers at the Broad Institute of MIT and Harvard, Koch Institute at MIT, Dana-Farber Cancer Institute (DFCI), and Massachusetts General Hospital have just released data demonstrating that nearly 90% of a tumor's genetic features can be detected in blood samples using whole-exome sequencing, and that the method can be effectively…
Published on September 22, 2017
Patient-centric genomics company DxTerity announced it will collaborate with California-based City or Hope Medical Center on the clinical development of a blood test intended to predict whether patients about to undergo radiation therapy for cancer are likely to benefit from the treatment. The test will also seek to provide information…
Published on September 11, 2017
Qiagen has selected Angle’s Parsortix system as its circulating tumor cell (CTC) harvesting technology, and Parsortix will be cross-promoted with Qiagen’s liquid biopsy solution portfolio, the companies said today, through a co-marketing agreement whose value was not disclosed. Angle and Qiagen have agreed to market to their customers the offerings…
Published on September 6, 2017
Epic Sciences said today its researchers have partnered with investigators at Memorial Sloan Kettering Cancer Center (MSK) to develop and apply a new liquid biopsy blood test shown to measure resistance to targeted therapies in metastatic castration-resistant prostate cancer (mCRPC) patients. The test—which measures tumor heterogeneity through analysis of single…
Published on July 24, 2017
Exosome Diagnostics, a developer of biofluid-based tests for cancer and other diseases, said today it has raised $30 million in an oversubscribed Series C financing. Exosome Diagnostics said it intends to use proceeds from the financing to support rapid commercial expansion of its ExoDx Prostate(IntelliScore) and other oncology tests—as well…
Published on June 13, 2017
Research from a team of scientists at the Johns Hopkins Bloomberg–Kimmel Institute for Cancer Immunotherapy, and other institutions, is shedding new light on the role of the DNA mismatch repair (MMR) pathway in the development of a variety of cancers and response to therapy. In a three-year clinical trial of…
Published on June 5, 2017
The more diverse the digestive tract bacteria, the slower the progression of metastatic melanoma in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center reported today. At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the researchers presented results from a…
Published on April 3, 2017
Biocept said today it has granted Oregon Health & Sciences University (OHSU) rights to commercially offer the molecular diagnostics developer’s Target Selector™ liquid biopsy testing services exclusively throughout Oregon. In addition, OHSU can use Biocept’s Target Selector assays in-house, and serve as a secondary laboratory for Biocept's research and testing…